Chenomx Inc. Announces Metabolic Profiling Services

Share Article

Chenomx Inc., a privately-held company that develops proprietary technologies for identifying and quantifying metabolites in complex biofluid mixtures, today announced the debut of metabolic profiling services, making Chenomx’s industry-leading metabolic profiling platform available to the worldwide research community.

Research scientists can now leverage Chenomx’s patented metabolic profiling technology without the need for in-house NMR spectrometers and expertise.

Chenomx Inc., a privately-held company that develops proprietary technologies for identifying and quantifying metabolites in complex biofluid mixtures, today announced the debut of metabolic profiling services, making Chenomx’s industry-leading metabolic profiling platform available to the worldwide research community.

Chenomx’s metabolic profiling services enable users to identify and quantify a broad range of metabolites in a number of biofluids, including blood, urine and cell extracts. The information contained in these metabolic profiles can be used to monitor the efficacy of potential drug candidates, to identify pathological reactions to potential drug candidates, and to identify potential biomarkers for diagnostic or toxicological applications.

Chenomx’s metabolic profiling platform is a unique, patented combination of hardware and software optimized for identifying and quantifying metabolites in biofluids. Nuclear Magnetic Resonance (NMR) spectrometers with field strengths of up to 800 MHz form the hardware component of the platform, offering high-throughput analysis and sensitive, quantitative, unbiased detection of a broad range of metabolites. Chenomx’s patented NMR mixture analysis algorithms transform information-rich but complex NMR spectra into quantitative metabolic profiles. Chenomx’s software technology is deployed and in use at many of the world’s leading pharmaceuticals and academic research institutions.

“The launch of Chenomx’s metabolic profiling services will help us bring Chenomx’s metabolic profiling technology to the broader research community,” comments Neil Taylor, President and CEO of Chenomx. “Research scientists can now leverage Chenomx’s patented metabolic profiling technology without the need for in-house NMR spectrometers and expertise.”

For additional information on Chenomx’s metabolic profiling services, please visit http://www.chenomx.com/services.

About Chenomx, Inc.

Chenomx, Inc. is a privately-held company that specializes in developing complex mixture analysis technology for broad application in life science technologies. With world-class expertise in chemistry, pharmaceutical sciences, and computer software, Chenomx offers a broad range of software products, compound libraries, and services to support researchers worldwide. More information on Chenomx and its solutions is available at http://www.chenomx.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jack Newton
Visit website

Media